Literature DB >> 19995925

High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.

Caroline Barau1, Constance Delaugerre, Joséphine Braun, Nathalie de Castro, Valérie Furlan, Isabelle Charreau, Laurence Gérard, Caroline Lascoux-Combe, Jean-Michel Molina, Anne-Marie Taburet.   

Abstract

Raltegravir concentrations and human immunodeficiency virus type 1 (HIV-1) RNA levels in semen samples from 10 treatment-experienced HIV-1-infected patients were measured after 24 weeks of raltegravir-based highly active antiretroviral therapy (HAART). Semen and plasma HIV-1 RNA levels were below 100 copies/ml and 50 copies/ml, respectively, in all samples. The median raltegravir concentrations in semen samples (n=10) and in plasma samples (n=9) drawn simultaneously were 345 (range, 83 to 707) ng/ml and 206 (range, 106 to 986) ng/ml, respectively. The median semen-to-plasma ratio of raltegravir concentration was 1.42 (range, 0.52 to 6.66), indicating good although variable levels of drug penetration of raltegravir in the seminal compartment.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19995925      PMCID： PMC2812174          DOI： 10.1128/AAC.01261-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Validation of an automated real-time PCR protocol for detection and quantitation of HIV and HCV genomes in semen.

Authors:  Christophe Pasquier; Corinne Souyris; Nathalie Moinard; Louis Bujan; Jacques Izopet
Journal:  J Virol Methods       Date:  2006-07-14       Impact factor: 2.014

Review 2.  Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment.

Authors:  Y-J Cao; C W Hendrix
Journal:  Clin Pharmacol Ther       Date:  2007-10-05       Impact factor: 6.875

3.  Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

Authors:  M Iwamoto; L A Wenning; A S Petry; M Laethem; M De Smet; J T Kost; S A Merschman; K M Strohmaier; S Ramael; K C Lasseter; J A Stone; K M Gottesdiener; J A Wagner
Journal:  Clin Pharmacol Ther       Date:  2007-08-22       Impact factor: 6.875

4.  Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection.

Authors:  Lauriane Goldwirt; Aurélie Barrail-Tran; Maria Da Cruz; Anne-Marie Taburet; Valérie Furlan
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-11-11       Impact factor: 3.205

5.  Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.

Authors:  Jade Ghosn; Marie-Laure Chaix; Gilles Peytavin; Jean-Louis Bresson; Julie Galimand; Pierre-Marie Girard; François Raffi; Isabelle Cohen-Codar; Jean-François Delfraissy; Christine Rouzioux
Journal:  J Antimicrob Chemother       Date:  2008-03-13       Impact factor: 5.790

Review 6.  Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.

Authors:  Jamie D Croxtall; Susan J Keam
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

7.  Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

Authors:  Nathalie De Castro; Joséphine Braun; Isabelle Charreau; Gilles Pialoux; Laurent Cotte; Christine Katlama; François Raffi; Laurence Weiss; Jean-Luc Meynard; Yazdan Yazdanpanah; Constance Delaugerre; Isabelle Madelaine-Chambrin; Jean-Pierre Aboulker; Jean-Michel Molina
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

8.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Authors:  Jeffrey L Lennox; Edwin DeJesus; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Daniel S Berger; Jing Zhao; Xia Xu; Angela Williams-Diaz; Anthony J Rodgers; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar
Journal:  Lancet       Date:  2009-08-03       Impact factor: 79.321

9.  Raltegravir with optimized background therapy for resistant HIV-1 infection.

Authors:  Roy T Steigbigel; David A Cooper; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Bach-Yen Nguyen; Hedy Teppler
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein.

Authors:  Maurizio Cianfriglia; Maria Luisa Dupuis; Agnese Molinari; Antonio Verdoliva; Roberta Costi; Clementina Maria Galluzzo; Mauro Andreotti; Andrea Cara; Roberto Di Santo; Lucia Palmisano
Journal:  Retrovirology       Date:  2007-03-07       Impact factor: 4.602
View more
  11 in total

1.  Raltegravir penetration in seminal plasma of healthy volunteers.

Authors:  Andrea Calcagno; Stefano Bonora; Antonio D'Avolio; Marco Siccardi; Marco Simiele; Mattia Chiesa; Daniel Gonzalez de Requena; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

2.  Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.

Authors:  Caroline Mitchell; Emily Roemer; Evangelyn Nkwopara; Brian Robbins; Theodore Cory; Tessa Rue; Courtney V Fletcher; Lisa Frenkel
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

3.  Characterization of binding of raltegravir to plasma proteins.

Authors:  Caroline Barau; Valérie Furlan; Yazdan Yazdanpanah; Catherine Fagard; Jean-Michel Molina; Anne-Marie Taburet; Aurélie Barrail-Tran
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

Review 4.  Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.

Authors:  Christine R Trezza; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

5.  Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).

Authors:  Cyril Clavel; Gilles Peytavin; Roland Tubiana; Cathia Soulié; Catherine Crenn-Hebert; Isabelle Heard; François Bissuel; Houria Ichou; Claudia Ferreira; Christine Katlama; Anne-Geneviève Marcelin; Laurent Mandelbrot
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

6.  Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.

Authors:  M Tozammel Hoque; Olena Kis; María F De Rosa; Reina Bendayan
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

Review 7.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

8.  A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.

Authors:  Martina Kovarova; Michael D Swanson; Rosa I Sanchez; Caroline E Baker; Justin Steve; Rae Ann Spagnuolo; Bonnie J Howell; Daria J Hazuda; J Victor Garcia
Journal:  J Antimicrob Chemother       Date:  2016-03-21       Impact factor: 5.790

9.  Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir.

Authors:  Darren M Moss; Wai San Kwan; Neill J Liptrott; Darren L Smith; Marco Siccardi; Saye H Khoo; David J Back; Andrew Owen
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

10.  The use of preexposure treatments for HIV prophylaxis.

Authors:  Adrian Majid; Robert R Redfield; Bruce L Gilliam
Journal:  HIV AIDS (Auckl)       Date:  2012-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.